Medical News

---

• Factors linked to homicide by schizophrenia patients revealed
• Gender differences in outcome after acute mania
• Injectable contraceptive users have increased VTE risk
• FDA approves dabigatran for stroke prevention in AF
• Extended prostate biopsy predicts improved progression-free survival
• High-dose fulvestrant benefits advanced breast cancer patients
• Frozen-thawed cycles significantly reduce pregnancy, live birth rates
• CVD risk factors show pronounced parent–child associations
• Neutrophils promote early atherosclerosis
• Parity increases diabetes risk in young Danish women
• Efficacy of linagliptin plus metformin for treating Type 2 diabetes confirmed
• AMI rates rose during stock market crash
• One in four with AF stops warfarin within first year

Factors linked to homicide by schizophrenia patients revealed Posted: 25 Oct 2010 05:00 PM PDT Substance misuse and treatment non-compliance are potentially modifiable risk factors associated with the perpetration of homicide among patients with schizophrenia and other psychoses, research shows.

Gender differences in outcome after acute mania Posted: 25 Oct 2010 05:00 PM PDT Results from a Spanish study suggest that there are small but significant differences in short- and long-term outcomes between men and women who have suffered an acute episode of pure mania

Injectable contraceptive users have increased VTE risk Posted: 24 Oct 2010 05:00 PM PDT Users of the injectable contraceptive depot–medroxyprogesterone acetate are nearly four times more likely to develop venous thromboembolism than nonusers of hormonal contraceptives, study findings indicate.

FDA approves dabigatran for stroke prevention in AF Posted: 24 Oct 2010 05:00 PM PDT The US Food and Drug Administration has approved the direct thrombin inhibitor dabigatran to prevent stroke and embolism in patients with atrial fibrillation.

Extended prostate biopsy predicts improved progression-free survival Posted: 24 Oct 2010 05:00 PM PDT US study results indicate that prostate biopsy protocols involving a greater number of cores are significantly associated with improved biochemical progression-free survival compared with protocols that remove fewer cores.

High-dose fulvestrant benefits advanced breast cancer patients Posted: 24 Oct 2010 05:00 PM PDT Patients taking high-dose fulvestrant for advanced breast cancer experience a longer period without disease progression than patients taking lower-dose fulvestrant, study findings indicate.

Frozen-thawed cycles significantly reduce pregnancy, live birth rates Posted: 24 Oct 2010 05:00 PM PDT Women who undergo oocyte slow-cooling preservation are significantly less likely to have a live birth after IVF than those undergoing treatment using fresh oocytes, suggest Italian study findings.

CVD risk factors show pronounced parent–child associations Posted: 24 Oct 2010 05:00 PM PDT Lifestyle factors such as diet, exercise, and smoking influence cardiovascular disease risk profiles within biological families, German researchers have shown.

Neutrophils promote early atherosclerosis Posted: 24 Oct 2010 05:00 PM PDT Researchers have found that neutrophils have an important role in the initiation of atherosclerosis, opening up the possibility of new targets for preventive therapies.

Parity increases diabetes risk in young Danish women Posted: 24 Oct 2010 05:00 PM PDT Study findings show that young women who have given birth to more than one child have an increased risk for diabetes compared with those who have experienced just one birth.

Efficacy of linagliptin plus metformin for treating Type 2 diabetes confirmed Posted: 24 Oct 2010 05:00 PM PDT Results from a randomized, placebo controlled study confirm that linagliptin is an effective add-on to metformin for improving glycemic control in patients with Type 2 diabetes.

AMI rates rose during stock market crash Posted: 24 Oct 2010 05:00 PM PDT Acute myocardial infarction rates in the USA rose markedly as stock market values plunged during the severe recession spanning the end of 2008 and early 2009, research suggests.

One in four with AF stops warfarin within first year Posted: 24 Oct 2010 05:00 PM PDT Around one in four patients newly starting warfarin therapy for atrial fibrillation stops taking it in the first year, despite a low overall rate of hospitalizations for hemorrhage, a large community-based study in the USA shows.

You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610